IMCR — Immunocore Holdings Income Statement
0.000.00%
Last trade - 00:00
- $5.66bn
- $5.26bn
- $249.43m
- 84
- 13
- 74
- 57
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 20-F | 10-K | 10-K | 10-K |
Standards: | IFRS | IFRS | USG | USG | USG |
Status: | fx Final | fx Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 32.8 | 38.6 | 36.5 | 174 | 249 |
Cost of Revenue | |||||
Gross Profit | — | — | 36.5 | 173 | 248 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 184 | 149 | 211 | 228 | 309 |
Operating Profit | -151 | -111 | -175 | -53.4 | -59.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -161 | -112 | -180 | -40.9 | -60.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -133 | -95 | -180 | -52.5 | -55.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -133 | -95 | -180 | -52.5 | -55.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -133 | -95 | -180 | -52.5 | -55.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.13 | -2.32 | -4.24 | -1.13 | -1.13 |